A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Canagliflozin (Primary)
- Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CREDENCE
- Sponsors Janssen Research & Development; Janssen-Cilag
- 01 Sep 2024 Results of a secondary analysis assessing effect of canagliflozin on kidney and cardiovascular events and safety outcomes in individuals with type 2 diabetes and chronic kidney disease published in the Diabetes, Obesity and Metabolism
- 01 Apr 2024 Results assessing the association of angiopoietin 2 and VEGF-A with cardiorenal outcomes and investigated the effect of canagliflozin on angiopoietin 2 and VEGF-A concentration, published in the Clinical Journal of The American Society of Nephrology: CJASN
- 04 Jan 2024 Results of pooled analysis from CANVAS Program and CREDENCE assessing Treatment effect of canagliflozin for patients on therapy for heart failure, published in the International Journal of Cardiology